AU7556994A - Methods for the diagnosis of alzheimer's disease - Google Patents
Methods for the diagnosis of alzheimer's diseaseInfo
- Publication number
- AU7556994A AU7556994A AU75569/94A AU7556994A AU7556994A AU 7556994 A AU7556994 A AU 7556994A AU 75569/94 A AU75569/94 A AU 75569/94A AU 7556994 A AU7556994 A AU 7556994A AU 7556994 A AU7556994 A AU 7556994A
- Authority
- AU
- Australia
- Prior art keywords
- alzheimer
- diagnosis
- disease
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10592293A | 1993-08-13 | 1993-08-13 | |
| US105922 | 1993-08-13 | ||
| PCT/US1994/008903 WO1995005604A2 (en) | 1993-08-13 | 1994-08-15 | Methods for the diagnosis of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU7556994A true AU7556994A (en) | 1995-03-14 |
Family
ID=22308530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU75569/94A Abandoned AU7556994A (en) | 1993-08-13 | 1994-08-15 | Methods for the diagnosis of alzheimer's disease |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU7556994A (en) |
| WO (1) | WO1995005604A2 (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6319498B1 (en) | 1995-03-14 | 2001-11-20 | Praecis Pharmaceuticals Incorporated | Modulators of amyloid aggregation |
| US5854215A (en) * | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals Incorporated | Modulators of β-amyloid peptide aggregation |
| US6303567B1 (en) | 1995-03-14 | 2001-10-16 | Praecis Pharmaceuticals, Inc . | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
| US5817626A (en) * | 1995-03-14 | 1998-10-06 | Praecis Pharmaceuticals Incorporated | Modulators of beta-amyloid peptide aggregation |
| ATE250766T1 (en) * | 1995-08-16 | 2003-10-15 | Aventis Pharma Inc | METHOD FOR DETERMINING THE DEGREE OF AGGREGATION OF THE BETA A4 PEPTIDE |
| AU7142796A (en) * | 1995-10-02 | 1997-04-28 | Erasmus University Rotterdam | Diagnosis method and reagents |
| US6277826B1 (en) | 1996-08-27 | 2001-08-21 | Praecis Pharmaceuticals, Inc. | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
| US5985242A (en) * | 1995-10-27 | 1999-11-16 | Praecis Pharmaceuticals, Inc. | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
| US5919631A (en) * | 1996-07-17 | 1999-07-06 | Hoechst Marion Roussel, Inc. | Method of determining the degree of aggregation of the β-A4 peptide |
| FR2751412B3 (en) * | 1996-07-17 | 1998-09-25 | Valbiofrance | METHODS OF IN VITRO DIAGNOSIS OF NEURODEGENERATIVE DISEASES AND KITS FOR THE IMPLEMENTATION OF THESE METHODS |
| US5985581A (en) * | 1996-07-25 | 1999-11-16 | The Mclean Hospital Corporation | Use of presenilin-1 for diagnosis of alzheimers disease |
| WO1998040748A1 (en) * | 1997-03-14 | 1998-09-17 | Neuromark | Diagnosing neurologic disorders |
| BR9916449A (en) | 1998-12-23 | 2002-01-22 | Univ Sydney | Test device, methods for determining a disease condition or a disorder or a propensity for the development of a disease condition or a disorder and for treating cancer or a propensity for the development of cancer in a human animal or non-human, use of an array of molecules, and, method for identifying a mimetic protein in a chemical or biological sample |
| JP2002543043A (en) | 1999-03-04 | 2002-12-17 | プラエシス ファーマシューティカルズ インコーポレーテッド | Modulator of aggregation of beta amyloid peptide containing D-amino acids |
| US9845427B2 (en) | 2009-10-20 | 2017-12-19 | Self-Suspending Proppant Llc | Proppants for hydraulic fracturing technologies |
| US9297244B2 (en) | 2011-08-31 | 2016-03-29 | Self-Suspending Proppant Llc | Self-suspending proppants for hydraulic fracturing comprising a coating of hydrogel-forming polymer |
| US20140000891A1 (en) | 2012-06-21 | 2014-01-02 | Self-Suspending Proppant Llc | Self-suspending proppants for hydraulic fracturing |
| US9868896B2 (en) | 2011-08-31 | 2018-01-16 | Self-Suspending Proppant Llc | Self-suspending proppants for hydraulic fracturing |
| US9315721B2 (en) | 2011-08-31 | 2016-04-19 | Self-Suspending Proppant Llc | Self-suspending proppants for hydraulic fracturing |
| US9932521B2 (en) | 2014-03-05 | 2018-04-03 | Self-Suspending Proppant, Llc | Calcium ion tolerant self-suspending proppants |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991008309A1 (en) * | 1989-12-05 | 1991-06-13 | New England Medical Center Hospitals, Inc. | Methods for detection of neurodegenerative disease |
| AU7121191A (en) * | 1990-02-26 | 1991-10-10 | Albert Einstein College Of Medicine Of Yeshiva University | Diagnostic assay for alzheimer's disease |
| AU8215391A (en) * | 1990-06-29 | 1992-01-23 | Case Western Reserve University | Diagnostic and prognostic methods based on soluble derivatives of the beta amyloid protein precursor |
| US5429947A (en) * | 1992-06-17 | 1995-07-04 | Merril; Carl R. | Diagnosing Alzheimer's disease and schizophrenia |
| US5397712A (en) * | 1992-07-28 | 1995-03-14 | University Of Cincinnati | Method to aid in the diagnosis of alzheimer's disease |
-
1994
- 1994-08-15 AU AU75569/94A patent/AU7556994A/en not_active Abandoned
- 1994-08-15 WO PCT/US1994/008903 patent/WO1995005604A2/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO1995005604A3 (en) | 2001-09-13 |
| WO1995005604A2 (en) | 1995-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2414092A (en) | Diagnostic method for alzheimer's disease | |
| AU5508798A (en) | Diagnostic and therapeutic reagents for alzheimer's disease | |
| ZA9410095B (en) | Methods of inhibiting Alzheimer's Disease | |
| IL105216A0 (en) | Method and kit for the diagnosis of alzheimer's disease | |
| AU7556994A (en) | Methods for the diagnosis of alzheimer's disease | |
| AU1407399A (en) | Treatment for alzheimer's disease | |
| AU2765992A (en) | Method for screening for alzheimer's disease | |
| GB9316727D0 (en) | Models of alzheimers's disease | |
| AU8392291A (en) | Tachykinin agonists for treatment of alzheimer's disease | |
| AU6905391A (en) | Methods and compositions for the treatment of hodgkin's disease | |
| AU3891499A (en) | Diagnostic tests for alzheimer's disease | |
| AU7708498A (en) | Nematode model for alzheimer's disease | |
| AU5857296A (en) | Use of leukotriene antagonists for alzheimer's disease | |
| AU4636993A (en) | Diagnosing alzheimer's disease and schizophrenia | |
| AU5053296A (en) | Pharmaceutical agents for the treatment of Alzheimer's disease | |
| AU5153398A (en) | Diagnostic method for the detection of alzheimer's disease in living patients | |
| AU1405899A (en) | Treatment for alzheimer's disease | |
| AU3068899A (en) | Diagnostic assay for late-onset alzheimer's disease | |
| AU9017098A (en) | Method for diagnosing alzheimer's disease | |
| AU7201696A (en) | Method of diagnosing crohn's disease | |
| AU1072195A (en) | Diagnosis of alzheimer's disease | |
| AU4841296A (en) | Diagnosis of and compositions and methods for the treatment of disease | |
| AU2990692A (en) | Diagnostic method for pompe's disease | |
| AU4781193A (en) | Clinical test for detection of alzheimer's disease | |
| AU7467094A (en) | Method of diagnosing alzheimer's disease |